Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
Sarcoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Surgery is often the principal means of diagnosis and is the primary treatment for all patients with uterine sarcoma. If the diagnosis is known, the extent of surgery is planned according to the stage of the tumor. Hysterectomy is usually performed when a uterine malignancy is suspected, except for rare instances when preservation of the uterus in a young patient is deemed safe for the type of cancer (e.g., a totally confined low-grade leiomyosarcoma in a woman who desires to retain childbearing potential). Medically suitable patients with the preoperative diagnosis of uterine sarcoma are considered candidates for abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy. Cytologic washings are obtained from the pelvis and abdomen. Thorough examination of the diaphragm, omentum, and upper abdomen is performed.
There is no firm evidence from a prospective study that adjuvant chemotherapy or radiation therapy is of benefit for patients with uterine sarcoma.[1] In one Gynecologic Oncology Group (GOG) study, the use of adjuvant doxorubicin did not alter the survival rate of patients with resected stage I or stage II uterine sarcomas; however, interpretation of these results is difficult because this study included some patients who received radiation and three types of uterine sarcomas that have variable responses to doxorubicin.[1][Level of evidence A1] Because the risk of disease recurrence is high, even with localized presentations, many physicians have considered the use of adjuvant chemotherapy or radiation therapy.[2] Another GOG study (GOG-0150 [NCT00002546]) addressed radiation therapy versus adjuvant chemotherapy.[3]
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for stage I uterine sarcoma include:
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy).
Surgery plus pelvic radiation therapy.
Surgery plus adjuvant chemotherapy.
Surgery plus adjuvant radiation therapy.
A nonrandomized Gynecologic Oncology Group study examined the effect of pelvic radiation therapy on patients with stage I and II carcinosarcomas. Patients who had pelvic radiation therapy had a significant reduction in tumor recurrences within the radiation treatment field but no alteration in survival.[1] A large nonrandomized study demonstrated improved survival and a lower local failure rate in patients with mixed mullerian tumors following postoperative external and intracavitary radiation therapy.[2] One nonrandomized study that predominantly included patients with carcinosarcomas showed that adjuvant chemotherapy with cisplatin and doxorubicin benefitted participants.[3]
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for stage II uterine sarcoma include:
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy).
Surgery plus pelvic radiation therapy.
Surgery plus adjuvant chemotherapy.
Surgery plus adjuvant radiation therapy.
A nonrandomized Gynecologic Oncology Group study examined the effect of pelvic radiation therapy on patients with stage I and II carcinosarcomas. Patients who had pelvic radiation therapy had a significant reduction in tumor recurrences within the radiation treatment field but no alteration in survival.[1] One nonrandomized study that predominantly included patients with carcinosarcomas showed that adjuvant chemotherapy with cisplatin and doxorubicin benefitted participants.[2]
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for stage III uterine sarcoma include:
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic selective lymphadenectomy, and resection of all gross tumor).
Surgery plus pelvic radiation therapy (under clinical evaluation).
Surgery plus adjuvant chemotherapy (under clinical evaluation).
Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas [3] and a 17.2% partial response rate in patients with leiomyosarcomas.[2]
GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[4][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[5] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[5][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.
Sources: 4 · Level of evidence A1 · GOG-0161 · 5 · 5 · Level of evidence A1
A role for chemotherapy as an adjuvant to surgery has not been established.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
There is currently no standard therapy for patients with stage IV disease. These patients should enroll in an ongoing clinical trial.
Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[2] a 33% response rate in patients with endometrial stromal cell sarcomas,[3], and a 17.2% partial response rate in patients with leiomyosarcomas.[4] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for advanced disease.[5,6] Cisplatin has activity as first-line therapy and minimal activity as second-line therapy for patients with carcinosarcomas, but cisplatin is inactive as first- or second-line therapy for patients with leiomyosarcomas.[1,7]
GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[8][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[9] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[9][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.
Sources: 8 · Level of evidence A1 · GOG-0161 · 9 · 9 · Level of evidence A1
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
There is currently no standard therapy for patients with recurrent disease. These patients should enroll in an ongoing clinical trial.
Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[2] a 33% response rate in patients with endometrial stromal cell sarcomas,[3] and a 17.2% partial response rate in patients with leiomyosarcomas.[4] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for recurrent disease.[5,6] Cisplatin has activity as first-line therapy and minimal activity as second-line therapy for patients with carcinosarcomas, but cisplatin is inactive as first- or second-line therapy for patients with leiomyosarcomas.[1,7] A regimen of gemcitabine plus docetaxel had a 53% response rate in patients with unresectable leiomyosarcomas and is undergoing further study.[8]
GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[9][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[10] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[10][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.
Sources: 9 · Level of evidence A1 · GOG-0161 · 10 · 10 · Level of evidence A1
Radiation therapy may be an effective method of palliative care for patients with carcinosarcoma who have localized recurrence in the pelvis confirmed by computed tomography. Phase I and II clinical trials are appropriate for patients who have disease recurrence with distant metastasis and are unresponsive to first-line phase II trials. High-dose progesterone hormone therapy may be of some benefit to patients with low-grade stromal sarcoma.[11]
Sources: 11
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Anything that increases a person's chance of getting a disease is called a risk factor. Not every person with one or more of these risk factors will develop an uterine sarcoma, and it will develop in some people who don't have any known risk factors. Talk with your doctor if you think you may be at risk. Risk factors for uterine sarcoma include:
Sources: risk factor
Past treatment with radiation therapy to the pelvis.
Sources: radiation therapy
Treatment with tamoxifen for breast cancer. If you are taking this drug, have a pelvic exam every year and report any vaginal bleeding (other than menstrual bleeding) as soon as possible.
Sources: tamoxifen · breast cancer · drug · pelvic exam · vaginal · menstrual
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Surgery is used to diagnose, stage, and treat uterine sarcoma. During this surgery, the doctor removes as much of the cancer as possible. The following procedures may be used to diagnose, stage, and treat uterine sarcoma:
Sources: Surgery · diagnose · uterine sarcoma
Laparotomy: A surgical procedure in which an incision (cut) is made in the wall of the abdomen to check the inside of the abdomen for signs of disease. The size of the incision depends on the reason the laparotomy is being done. Sometimes organs are removed or tissue samples are taken and checked under a microscope for signs of disease.
Sources: Laparotomy · surgical · incision
Abdominal and pelvic washings: A procedure in which a saline solution is placed into the abdominal and pelvic body cavities. After a short time, the fluid is removed and viewed under a microscope to check for cancer cells.
Total abdominal hysterectomy: A surgical procedure to remove the uterus and cervix through a large incision (cut) in the abdomen.
Sources: Total abdominal hysterectomy · cervix
Bilateral salpingo-oophorectomy: Surgery to remove both ovaries and both fallopian tubes.
Sources: Bilateral salpingo-oophorectomy · ovaries
Lymphadenectomy: A surgical procedure in which lymph nodes are removed and checked under a microscope for signs of cancer. For a regional lymphadenectomy, some of the lymph nodes in the tumor area are removed. For a radical lymphadenectomy, most or all of the lymph nodes in the tumor area are removed. This procedure is also called lymph node dissection.
Sources: Lymphadenectomy · lymph nodes · regional lymphadenectomy · radical lymphadenectomy
Treatment in addition to surgery may be given, as described in the Treatment Option Overview section of this summary.
Sources: Treatment Option Overview
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The cancer may come back in the uterus, the pelvis, or in other parts of the body.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
There are different types of treatment for patients with uterine sarcoma.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy
Chemotherapy
Hormone therapy
New types of treatment are being tested in clinical trials.
Treatment for uterine sarcoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up care may be needed.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Different types of treatments are available for patients with uterine sarcoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: uterine sarcoma · standard · clinical trials · research study · cancer
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Surgery is the most common treatment for uterine sarcoma, as described in the Stages of Uterine Sarcoma section of this summary.
Sources: Surgery · Stages of Uterine Sarcoma
After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · radiation therapy · cells · adjuvant therapy
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: External radiation therapy
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat uterine sarcoma, and may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: stage · palliative therapy · symptoms · quality of life
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Sources: drugs · injected · vein · systemic chemotherapy
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances produced by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working.
Sources: Hormone therapy · hormones · glands · receptors
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of stage I leiomyosarcoma of the uterus, stage I endometrial stromal sarcoma, and stage I adenosarcoma of the uterus may include:
Sources: stage I leiomyosarcoma of the uterus · stage I endometrial stromal sarcoma · stage I adenosarcoma of the uterus
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy).
Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy
Surgery followed by radiation therapy to the pelvis.
Sources: radiation therapy · pelvis
Surgery followed by chemotherapy.
Sources: chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of stage II leiomyosarcoma of the uterus, stage II endometrial stromal sarcoma, and stage II adenosarcoma of the uterus may include:
Sources: stage II leiomyosarcoma of the uterus · stage II endometrial stromal sarcoma · stage II adenosarcoma of the uterus
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy).
Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy
Surgery followed by radiation therapy to the pelvis.
Sources: radiation therapy · pelvis
Surgery followed by chemotherapy.
Sources: chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of stage III leiomyosarcoma of the uterus, stage III endometrial stromal sarcoma, and stage III adenosarcoma of the uterus may include:
Sources: stage III leiomyosarcoma of the uterus · stage III endometrial stromal sarcoma · stage III adenosarcoma of the uterus
Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, lymphadenectomy, and removal of all other tissue where tumor is found).
Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy · tissue
A clinical trial of surgery followed by radiation therapy to the pelvis.
Sources: clinical trial · radiation therapy · pelvis
A clinical trial of surgery followed by chemotherapy.
Sources: chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
There is no standard treatment for patients with stage IV leiomyosarcoma of the uterus, stage IV endometrial stromal sarcoma, or stage IV adenosarcoma of the uterus. Treatment may include a clinical trial using chemotherapy.
Sources: standard treatment · stage IV leiomyosarcoma of the uterus · stage IV endometrial stromal sarcoma · stage IV adenosarcoma of the uterus · clinical trial · chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
For information about the treatments listed below, visit the Treatment Option Overview section.
Sources: Treatment Option Overview
There is no standard treatment for recurrent uterine sarcoma. Treatment may include a clinical trial using chemotherapy.
Sources: standard treatment · recurrent · uterine sarcoma · clinical trial · chemotherapy
For patients with recurrent carcinosarcoma (a certain type of tumor), treatment may include:
Sources: carcinosarcoma · tumor
Radiation therapy as palliative therapy to relieve symptoms (such as pain, nausea, or bowel problems) and improve the quality of life.
Sources: Radiation therapy · palliative therapy · symptoms · nausea · bowel · quality of life
Hormone therapy.
Sources: Hormone therapy
A clinical trial of a new treatment.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Sarcoma
ClinicalTrials.gov recordRecurrent Uterine Sarcoma, Uterine Carcinosarcoma
ClinicalTrials.gov recordRecurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma
ClinicalTrials.gov recordLeiomyosarcoma
ClinicalTrials.gov recordRecurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma,...
ClinicalTrials.gov recordRecurrent Uterine Sarcoma, Uterine Carcinosarcoma
ClinicalTrials.gov recordStage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB...
ClinicalTrials.gov recordStage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
ClinicalTrials.gov recordStage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB...
ClinicalTrials.gov recordMetastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
ClinicalTrials.gov recordCarcinosarcoma, Ovarian
ClinicalTrials.gov recordLeiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine
ClinicalTrials.gov recordTreatment of Recurrent Uterine Sarcoma
Treatment of Stage I Uterine Sarcoma
Treatment of Stage II Uterine Sarcoma
Treatment of Stage III Uterine Sarcoma
Treatment of Stage IV Uterine Sarcoma
Uterine Sarcoma